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AbstrACt
Introduction This protocol outlines the rationale, design 
and methods for the process and feasibility evaluations of 
the primary care management on knee pain and function 
in patients with knee osteoarthritis (PARTNER) study. 
PARTNER is a randomised controlled trial to evaluate 
a new model of service delivery (the PARTNER model) 
against ‘usual care’. PARTNER is designed to encourage 
greater uptake of key evidence- based non- surgical 
treatments for knee osteoarthritis (OA) in primary care. The 
intervention supports general practitioners (GPs) to gain an 
understanding of the best management options available 
through online professional development. Their patients 
receive telephone advice and support for OA management 
by a centralised, multidisciplinary ‘Care Support Team’. We 
will conduct concurrent process and feasibility evaluations 
to understand the implementation of this new complex 
health intervention, identify issues for consideration when 
interpreting the effectiveness outcomes and develop 
recommendations for future implementation, cost 
effectiveness and scalability.
Methods and analysis The UK Medical Research 
Council Framework for undertaking a process evaluation 
of complex interventions and the Reach, Effectiveness, 
Adoption, Implementation and Maintenance (RE- AIM) 
frameworks inform the design of these evaluations. 
We use a mixed- methods approach including analysis 
of survey data, administrative records, consultation 
records and semistructured interviews with GPs and 
their enrolled patients. The analysis will examine fidelity 
and dose of the intervention, observations of trial 
setup and implementation and the quality of the care 
provided. We will also examine details of ‘usual care’. 
The semistructured interviews will be analysed using 
thematic and content analysis to draw out themes around 
implementation and acceptability of the model.
Ethics and dissemination The primary and substudy 
protocols have been approved by the Human Research 
Ethics Committee of The University of Sydney (2016/959 
and 2019/503). Our findings will be disseminated to 
national and international partners and stakeholders, who 
will also assist with wider dissemination of our results 
across all levels of healthcare. Specific findings will be 
disseminated via peer- reviewed journals and conferences, 
and via training for healthcare professionals delivering OA 
management programmes. This evaluation is crucial to 
explaining the PARTNER study results, and will be used to 
determine the feasibility of rolling- out the intervention in 
an Australian healthcare context.
trial registration number ACTRN12617001595303; 
Pre- results.
IntroduCtIon
Osteoarthritis (OA) is a leading cause of 
lower limb pain and disability, affecting more 
than 2 million Australians.1 Although there 
is no cure, there are effective non- surgical 
treatments for the long- term management 
of symptomatic OA.2 In particular, educa-
tion and advice on OA, exercise and phys-
ical activity and weight management are 
strengths and limitations of this study
 ► A comprehensive, preplanned, process and feasibili-
ty evaluation of a complex model of service delivery.
 ► Mixed- methods approach, underpinned by theo-
retical frameworks for design and evaluation of 
complex health interventions and chronic disease 
management.
 ► Codesigned by a broad range of stakeholders in-
cluding general practitioners, people with osteoar-
thritis, physiotherapists, rheumatologists, industry 
groups and policy makers.
 ► Outcomes from this study will directly contribute 
to the implementation priorities of the Australian 
‘National Osteoarthritis Strategy’.
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Figure 1 The PARTNER logic model. Theoretical basis for the development of the PARTNER model of service delivery, and 
the mechanisms underpinning the process evaluation. COM- B, capability, opportunity, motivation and behaviour; GP, general 
practitioner; INCA, integrated care management software (formally cdmNET); PARTNER, primary care management on knee 
pain and function in patients with knee osteoarthritis; RACGP, Royal Australian College of General Practitioners.
the core interventions recommended by current clin-
ical guidelines.3–5 These treatments are, however, often 
underutilised in primary care, and day- to- day manage-
ment of Australians with knee OA is inconsistent with 
these recommendations.6 We designed the Effectiveness 
of a new model of primary care management on knee 
pain and function in patients with knee osteoarthritis 
(PARTNER) study, to address this issue.7 The aim of the 
PARTNER study is to test a new model of service delivery 
(the PARTNER model), designed to encourage greater 
uptake of these key non- surgical treatments in primary 
care pathways, in comparison to usual care.
The PARTNER model is a complex health intervention 
(figure 1) employing multiple interacting components 
that target different organisational levels of healthcare 
delivery.8 The intervention will target both general prac-
titioners (GPs) and their patients with OA. GPs will be 
provided with online professional development opportu-
nities to gain an understanding of the effective conser-
vative, non- surgical management options available for 
treatment of patients with OA and endorsed by the 
Royal Australian College of General Practitioners. Their 
patients will receive tailored advice and support on issues 
related to the management of OA including physical 
activity and exercise, weight loss, pain management and 
other effective self- management behaviours. This support 
will be delivered remotely for 12 months by a centralised, 
multidisciplinary ‘Care Support Team’ (CST) of health 
professionals trained in best- practice management of OA 
and health behaviour change.
The effectiveness and cost- effectiveness of this new 
model is being tested through a two- arm, cluster 
randomised controlled trial (RCT), and the process and 
feasibility evaluations described here will be conducted 
concurrently with the RCT. These evaluations will help 
us to understand the factors influencing the implementa-
tion of the intervention, identify issues for consideration 
when interpreting the effectiveness results and enable us 
to develop recommendations for future implementation 
of the new model into Australian general practice. This 
process evaluation and feasibility protocol has two aims, 
namely:
1. To explain the PARTNER study results in terms of fi-
delity and engagement with the intervention, and 
determine:
1.1. Whether the intervention and control arms were 
delivered as intended for both the GPs and patients 
enrolled in the study.
1.2. What ‘usual care’ entailed, including types and 
rate of uptake of other services recommended for the 
patient.
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1.3. The types of issues typically identified or actioned 
during the consultations between the participants and 
the healthcare professionals in the study (ie, the GPs 
and CST), and determine the nature of the support 
and advice provided for each issue.
1.4. Participants’ (GPs and patients) and the CST per-
sonnel’s perspectives on how, why and for whom the 
intervention did or did not work.
1.5. Whether the primary and secondary outcome ef-
fects were due to the nature of the implementation, or 
to the intervention.9
2. To determine the feasibility and acceptability of having 
the model adopted broadly in an Australian health-
care context (if the study is found to be effective), 
specifically:
2.1. Are there potential barriers and enablers to rolling 
the model out in the Australian primary care setting 
that have not been identified previously? We will look 
at barriers and enablers at the patient level, profession-
al, organisational and service level (meso) and health 
systems level (macro).10
2.2. Do people with OA, and GPs, value the interven-
tion as it was delivered?
2.3. Are the results generalisable to other people with 
OA, healthcare service providers and to different 
Australian healthcare contexts (eg, public or private 
hospitals).
2.4. Is the intervention cost effective compared with 
usual care?
MEthods And AnAlysIs
the PArtnEr cluster rCt
The PARTNER study is an investigator- initiated prag-
matic RCT. A detailed explanation of the background, 
theoretical development and protocol for the broader 
PARTNER study (2016/959) has been described previ-
ously,7 11 and the trial prospectively registered with 
the Australia New Zealand Clinical Trials Registry 
(ACTRN12617001595303). The process and feasibility 
evaluations will be reported in accordance with the Stan-
dards for Reporting Implementation Studies, and the 
Consolidated Criteria for Reporting Qualitative Research 
guidelines.12 13
Briefly, the RCT is comparing the new PARTNER 
model of service delivery to usual care.7 We will recruit 
44 general practices and 572 patients with knee OA in 
urban and regional practices in Victoria and New South 
Wales, Australia. The patients will be 45 years of age or 
older, and have had knee pain (≥4/10) for a minimum 
of 3 months. The model has interventions for both the 
person with OA, and their GP. The GP intervention will 
provide professional development and training oppor-
tunities on the most current conservative, non- surgical 
management options available for OA, as recommended 
by national and international clinical guidelines.3–5 This 
will include audit/feedback activities, online learning 
modules and the Integrated Care electronic desktop IT 
support tool (previously named cdmNET). All GPs in 
the study regardless of group allocation will be asked to 
provide an initial evidence- based consultation for their 
participating patients. If allocated to the intervention 
arm, patients will be referred to the PARTNER CST. The 
CST is a centralised, multidisciplinary team of health 
professionals trained in best- practice OA management, 
and with skills in health behaviour change. The CST 
will support patient participants to manage their knee 
OA for a period of 12 months. The CST will provide the 
patients with education, advice and ongoing support for 
behaviour change on the key OA treatments, including 
leg strengthening exercises, general physical activity, 
weight loss and appropriate use of pain medications as 
agreed with the patient. Patients with a body mass index 
≥27 will have the option of completing the Common-
wealth Scientific and Industrial Research Organisation’s 
online ‘Total Wellbeing Diet’ (TWD) program.14 15 The 
TWD program is based on an evidence- based, struc-
tured, nutritionally balanced eating plan designed to be 
delivered as part of a balanced lifestyle programme.16 
Patient participants may also be directed to one or more 
secondary interventions or additional healthcare services 
if they meet the referral criteria and/or have identified 
it as a personal priority. These treatment options may 
include online cognitive behavioural therapy (CBT) 
programme for mood, pain coping and sleep or referrals 
to healthcare professionals (eg, physiotherapists or dieti-
cians) for face- to- face sessions. The primary outcomes 
of the PARTNER study are change in self- reported pain 
and function at 12 months. We will also assess a range of 
secondary patient- level outcomes at 6 and 12 months, and 
including the cost- effectiveness of the model.7
Patient and public involvement
One of the strengths of this process and feasibility evalua-
tion is that it has been incorporated into the overall study 
design from conception. Both the main protocol and this 
evaluation and feasibility subprotocol are underpinned 
by existing theoretical frameworks.17–21 It has built on 
considerable background work undertaken by our team, 
and with input from a broad range of stakeholders, GPs 
and consumers who participated in our five working 
groups: (1) scientific methods, (2) data, (3) GP model 
of service delivery, (4) consumer engagement and (5) 
policy and marketing. Each working group was chaired 
by an appropriate representative from either an industry 
partner, consumer group or other stakeholder organi-
sation. This process and feasibility evaluation protocol 
has had further input from colleagues with expertise in 
implementing and assessing health interventions, and its 
content has evolved after findings from our pilot work. 
We send 6 monthly updates on the study’s progress to our 
stakeholders and participants via an online newsletter.
theoretical frameworks for the process evaluation
Figure 1 outlines the PARTNER logic model, which 
summarises the key questions, target behaviours, 
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Table 1 Data collection methods used to address each aim 
and question of the process evaluation
Aims
Data collection method
i ii iii iv v vi
Aim 1: Explain the trial 
results in terms of fidelity and 
engagement:
            
1.1 Were the intervention and 
control arms delivered as 
intended:
            
GPs X X     X X
Patients X X X X X X
CST     X X     
1.2 What did ‘usual care’ entail?             
GPs   X     X   
Patients   X     X   
1.3 What types of issues were 
discussed or actioned during the 
interactions between the CST/
GPs and the patients?
            
GPs   X     X   
CST   X X X X   
1.4 Participants and healthcare 
professionals’ perspectives on 
how, why and for whom the 
interactions did or did not work? 
(semistructured qualitative 
interviews).
            
GPs         X   
CST         X   
Patients         X   
1.5 Were the primary and 
secondary outcome effects 
due to the nature of the 
implementation or to the 
intervention?
            
GPs   X     X   
Patients   X X X X   
Aim 2: Feasibility and 
acceptability of scaling the 
intervention in Australia
            
2.1 What are the possible barriers 
and enablers to rolling- out the 
model in Australian primary care?
            
GPs     X   X   
Patients     X   X   
2.2 Do patients and GPs value 
the intervention as delivered?
        X   
GPs         X   
Patients         X   
2.3 Are the results generalisable 
to other patients with OA, 
healthcare service providers and 
across states?
            
  X       X   
Continued
interventions, mediators and outcomes for both GPs 
and patients recruited to the study. The development of 
the model used Wagner’s theoretical framework for the 
management of chronic disease,17 the Behaviour Change 
Wheel and the Theoretical Domains Framework18 to 
identify key intervention components and propose a 
causal pathway between the study intervention and the 
main outcomes.
Our methods for the process and feasibility evalua-
tions are based on the recommendations from the UK 
Medical Research Council framework for undertaking 
a process evaluation of complex interventions.19 The 
RE- AIM (Reach, Effectiveness, Adoption, Implementa-
tion and Maintenance) framework has further guided 
the development of our evaluation questions.20 21 RE- AIM 
is recommended by the Osteoarthritis Research Society 
International for conducting implementation trials on 
OA.9 RE- AIM emphases the need to look into the propor-
tion and representativeness of the participants’ involved 
in the trial, the impact of the intervention, the fidelity and 
dose of the implementation and identify issues impacting 
on long- term scaling of the model. It covers five domains, 
briefly:
 ► Reach: did the intervention reach who we intended?
 ► Effectiveness: was the intervention effective and cost- 
effective? (this question is primarily addressed by the 
RCT)7
 ► Adoption: who do we need to target to develop insti-
tutional support for the intervention? Did the prac-
tices recruited to our study adopt the changes at an 
organisational level, how representative were these 
sites compared with other Australian settings and 
what needs to be undertaken to have it adopted more 
widely? Will actual change in the way OA is managed 
in primary care be achievable with our model, and 
how well do the end users (clinicians, patients and 
other service providers) accept the intervention and 
processes?9
 ► Implementation: was the intervention delivered 
correctly and consistently (fidelity) as intended at the 
trial outset?
 ► Maintenance: can the intervention be delivered 
sustainably in different healthcare contexts and more 
broadly?
data sources for the PArtnEr study
We will use a mixed- methods approach that uses both 
quantitative and qualitative methods to capture process 
data for analysis (table 1, figure 1), all of which involve 
informed consent and have been approved by an ethics 
committee. Detailed descriptions of the quantitative data 
collection instruments and analysis have been described 
previously in the main protocol,7 with details relevant to 
this protocol outlined below. The type and timing of data 
collected to address each aim of the process evaluation, 
including the details of the qualitative data collection are 
described in the following sections. Figure 2 illustrates 
the integration of the process and feasibility evaluations 
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Aims
Data collection method
i ii iii iv v vi
2.4 Is the intervention cost- 
effective compared with usual 
care?
            
Patients   X   X X   
i. Analysis of inclusion / exlusion criteria, screening logs and 
withdrawal logs. 
ii. Analysis of the quantitative data collected in electonic surveys 
for both the GPs and patients with OA. 
iii. Analysis of a sample of recorded telephone interactions 
between the CST responsible for providing the intervention and 
the patients with OA
iv. Audit of data collected over the trial (the electronic 
consultation notes) that captures the number, length and nature 
of the interactions between the CST and patients with OA. 
v. Semi- structured interviews with patient participants and the 
GPs and CST involved in the study.
vi. Audit of training logs and other activity logs for GPs in 
the intervention group. This includes analysis of web usage 
statistics.
Table 1 Continued
Figure 2 Indicative timing of the data collection processes for GPs and patients. This schematic illustrates the integration 
of the process and feasibility evaluations with the main RCT. Open boxes are quantitative data collection, filled boxes are 
qualitative data (interviews or phone call recordings). The patient intervention is for 12 months. *Data are collected for GPs in the 
intervention group only. CST, Care Support Team; GPs, general practitioners; Pt, patients; Q, online survey questionnaires.
with the main RCT. Briefly, the data collection methods 
and time points relevant to these evaluations include:
1. Study administration records: include participant track-
ing, screening, training, withdrawal and serious adverse 
event logs; and training logs for the GPs, CST and other 
trial staff. Data are collected for the duration of the trial.
2. Electronic survey data from patients and GP surveys. 
GPs complete surveys at baseline and after the study 
team has confirmed all their patients have attended 
their first GP consultation. Patients complete surveys 
at baseline, post GP visit, 3, 6 and 12 months.
3. Electronic consultation detailed records of each of the 
CSTs’ consultations with the intervention patients over 
the 12- month period.
4. Service provider records will be collected from exter-
nal providers delivering the weight- loss intervention, 
and the online CBT programme offered to the inter-
vention group (ie, painTrainer and ThisWayUp).
5. Recorded consultation phone calls between the pa-
tient and the CST: all patient consultations for the du-
ration of the patient’s involvement with the CST will be 
audio- recorded. For the first 18 weeks patients will be 
contacted once a fortnight on average (nine calls), and 
then monthly for the next 6 months (six calls). The 
actual number and timing of these calls will be agreed 
between the patient and the CST.
6. Semistructured qualitative interviews: these will be un-
dertaken with a selection of GPs, patients and the CST 
personnel. GP interviews will be undertaken after all 
their enrolled patients have had their initial GP visit. 
Patient interviews will be undertaken after they have 
completed their 12- month survey. The CST interviews 
will be undertaken after all patients have finished their 
last consultation.
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Quantitative data analysis to address the aims of the process 
evaluation
We will use a wide selection of the quantitative data to 
explain the study’s effectiveness results in terms of 
fidelity and engagement with the intervention, particu-
larly around the consistency of the study’s implementa-
tion as per the primary protocol (figure 1) and the trial 
procedures manuals (Aim 1.1). This will include the 
study administration records, the electronic survey data 
collected from both patients and GPs, the electronic 
consultation records from the CST and any changes 
required to the protocol over the duration of the study. 
For the GPs in the intervention group, we will also 
examine how many completed the required professional 
development training modules, the optional capacity 
building training modules and the number of interven-
tion patients who were ultimately referred to the CST 
with OA (ie, if there were any patients who were not diag-
nosed with OA). We will further examine if patients have 
reported receiving information on, or discussed with 
their GP, any of the four key topics (OA education, phys-
ical activity, muscle strengthening and weight loss), and 
whether OA management plans were prepared for each 
patient. To determine what usual care entailed for our 
control cohort (Aim 1.2), we will analyse the electronic 
survey data from both the GPs and patients, including if 
there were any unanticipated treatments prescribed or 
activities undertaken that may need to be addressed in a 
future roll- out of the model.
For the CST, we will analyse the study records and survey 
data to determine the amount of time spent with each 
patient, and whether the key interventions or secondary 
interventions (mood, pain and sleep management) were 
discussed in the consultations. Electronic patient survey 
data, the CST electronic consultation records and a selec-
tion of the recorded patient consultations will be further 
examined to establish what issues or topics were typically 
discussed during the consultations (Aim 1.3), including 
any additional issues that may need to be incorporated 
into the intervention long- term (also see the Qualitative 
data collection methods section). We will examine the 
nature of the support and advice provided to patients 
by both the GPs and the CST, map the frequency and 
accuracy of each treatment component to the interna-
tional care standards for OA (OA Quality Indicators)22 23 
and identify any conflicting advice that may need to be 
addressed when designing future training or educational 
materials.
We will also use the quantitative datasets to determine 
the feasibility and acceptability of having the model 
adopted broadly in an Australian healthcare context. We 
will explore healthcare providers’ and patients’ experi-
ence of the intervention and its perceived impact (Aim 
2.2 and 2.3) and examine any issues that arose during the 
trial that would affect broader implementation (Aim 2.1). 
We will undertake an audit of the inclusion and exclusion 
criteria, and the screening logs for general practices, GPs 
and patients to identify any reasons for not choosing to 
participate and for any loss to follow- up. These data will 
be compared with the general population to give an indi-
cation of the representativeness and generalisability of 
the results to other patients, healthcare service providers 
and other Australian states/territories. Collectively, these 
data will provide some insight into the generalisability of 
the efficacy results, and any amendments that may need 
to be incorporated into the current model. This informa-
tion will also be used to determine the cost effectiveness 
of the PARTNER model compared with usual care.7
Qualitative data collection
In addition to the quantitative datasets, we will collect 
and analyse qualitative data that will address many of the 
process and feasibility aims of this study (see table 1). 
First, we will analyse a sample of the telephone interac-
tions that have been recorded between the patients in the 
intervention group and the CST. After the final patient is 
recruited, we will purposively select 20 patients to conduct 
a detailed analysis of their telephone consultations. We 
aim to ensure maximum heterogeneity of sampling, 
based on clinical and demographic characteristics, and 
gain the perspectives of patients and GPs in both urban 
and regional/rural general practices and smaller versus 
larger practices. To capture the change in the perspectives 
over the 12 months, three phone calls will be analysed per 
person, covering the initial consultation—one randomly 
selected call from the first 18 weeks of the intervention 
(intensive phase), and one randomly selected call from 
the last 6 months of the CST intervention (maintenance 
phase). The phone recordings will be transcribed and 
analysed using predesigned checklists. The first checklist 
will be used to determine how much time is spent on the 
key priority topics and the targeted secondary interven-
tions (mood, pain coping and sleep; figure 1). A tally will 
be made of the different types of issues discussed during 
the calls and the type of information given (Aim 1.1, 1.3, 
1.5). We will also assess if the components of care deliv-
ered by the CST are accompanied by the appropriate 
behaviour change methods to support self- management 
as per the PARTNER protocol. We will use a checklist 
based on the methodology developed by our partner 
‘HealthChange Australia’ to train the CST in behaviour 
change techniques to examine the fidelity of the delivery 
of the behaviour change component of the intervention. 
This analysis will be undertaken by a member of the study 
team involved with the intervention, and an independent 
person not involved with running the trial. Data will be 
compiled and compared, and if required adjudicated by 
a third party.
Second, we will undertake semistructured qualita-
tive interviews with a selection of patients, GPs and the 
CST. These results will also address a range of the aims 
of these process and feasibility evaluations (table 1), and 
a primary focus on contextual factors affecting delivery 
and implementation, and thus those that influence roll-
ing- out and long- term sustainability of the PARTNER 
model (Aims 2.1, 2.2 and 2.3). The interviews will be 
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conducted over the telephone or face- to- face, by dedi-
cated researcher/s not involved with delivering the RCT 
and with experience in qualitative data collection. Our 
multidisciplinary research team will develop the semi-
structured interviews to explore issues around patients’, 
GPs’ and CST personnel’s perspectives on how, why and 
for whom the interventions did or did not work, positive 
and negative (unintentional) outcomes, possible barriers 
and facilitators to rolling- out the intervention, including 
any adoption considerations at the setting or organisa-
tional (meso) level, if the new model of care is valued by 
the users, and if they found any aspects burdensome (ie, 
the number of appointments for patients or the amount 
of training for GPs).
Similar to the selection of recorded CST phone consul-
tations, we will use purposive sampling to gain perspec-
tives from patients and GPs from different regional and 
practice- related contexts. This will include around 30 
patients (15 control and 15 intervention) and 14 GPs (7 
from each group), or until redundancy is observed. We 
will also interview all willing members of the CST. Patients 
will be different from those used in the examination of 
the telephone consultations with the CST and will have 
finished their involvement with the trial. The interviews 
will be conducted one- to- one and will take approximately 
1 hour each. Participants will be consented by the inter-
viewer over the phone. The interviews will follow an inter-
view guide which outlines the broad discussion topics. 
The draft interview schedule will be tested with patients 
and healthcare professional volunteers prior to use.
Qualitative data analysis plan
The semistructured interview data and content data will 
be thematically analysed and interpreted. Interviews will 
be audio- recorded and transcribed verbatim. Transcripts 
will be coded and analysed thematically, using methods 
of constant comparison derived from grounded theory.24 
Contextual information derived from other process data 
will be used to triangulate the identified themes. The 
logic model (figure 1) and process evaluation framework 
(table 1) will aid the analysis by triangulating the quanti-
tative data with the relevant qualitative data under each 
subheading. Qualitative data analysis software ‘NVivo’ 
(QSR International, Melbourne, Australia) will be used. 
Identified themes will be explored, looking for shared or 
disparate views among the patients, GPs and CST about 
their experiences of participation, implementation and 
operationalisation of the study at their practice (if rele-
vant). The collection and analysis of the qualitative data 
will be conducted iteratively so that themes identified in 
early interviews can be explored in more depth later.19
EthICs And dIssEMInAtIon
This protocol outlines the rationale, design and methods 
for process and feasibility evaluations of the PARTNER 
study, a RCT designed to test the new PARTNER model of 
service delivery. This evaluation of a complex intervention 
is crucial to explaining the PARTNER study results, and to 
determine the feasibility of scaling the intervention in an 
Australian healthcare context. The data and results will 
be used to identify and address issues in the intervention 
and improve the delivery of the model long- term, with a 
focus on effectiveness, quality and safety and scalability.
Outcomes from this study, regardless of the effective-
ness of the RCT, will directly contribute to the implemen-
tation priorities of the Australian ‘National Osteoarthritis 
Strategy’,25 the aligned jurisdictional Models of Care in 
Western Australia,26 New South Wales27 and Victoria,28 
and other associated national strategies.4 29 The National 
OA strategy has multi- partisan support from peak and 
professional bodies, governments, private health insurers 
and consumers to improve access to evidence- based, non- 
surgical OA interventions that deliver high- value care to 
all Australians with OA. It specifically calls for the prior-
itisation of testing and implementation of new models 
of service delivery to support referral to allied health 
and community- based services, assist primary care prac-
titioners to deliver essential lifestyle- based interventions 
and ultimately reduce the over- reliance on medications 
and joint replacement surgery. Our findings will be 
disseminated to all partners and stakeholders involved 
with both the study’s initial design, and those with an 
interest in its long- term implementation. The National 
OA Strategy Leadership Group and Implementation 
Advisory Committee will help drive dissemination of our 
results across all levels of healthcare to address the local, 
meso and macro needs identified. At an international 
level our results will contribute to the work of the Osteoar-
thritis Research Society International’s ‘Joint Effort Initia-
tive’ who are currently developing broadscale guidelines 
and recommendations to assist with the global implemen-
tation of OA management programs.30 Specific research 
findings will be disseminated via peer- reviewed journals 
and conferences, and we anticipate delivering training 
workshops for interested healthcare professionals.
In conclusion, this paper reports the design of the 
mixed- methods process and feasibility evaluations for 
the PARTNER study. The results will help us gain a better 
understanding of the implementation of the intervention 
and identify issues for consideration when interpreting 
its effectiveness. However, these evaluations will also allow 
us to identify any broader issues or considerations that 
will need to be addressed for a wider roll- out of this new 
model of service delivery in Australian primary care.
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